Progress in Development of Human Radiolabelled Mass Balance and Biotransformation Studies
MA Sheng1,2, YI Ling1, MIAO Li-yan1,2*
1. National Institution of Drug Clinical Trial, First Affiliated Hospital of Soochow University, Suzhou 215031, China; 2. Institute for Interdisciplinary Drug Research and Translational Sciences, College of Pharmaceutical Sciences, Soochow University,Suzhou 215031, China
Abstract：Recently,with the rapid development of new drug research in China, the human mass balance and biotransformation (MBB) studies on innovative drugs are on a track to become indispensable during new drug application. However, traditional analysis method, e.g. mass spectrum, is insufficient to elaborately explain the mass balance and the relative biotransformation of the investigated drugs in human bodies. This problem could be solved by applying radiolabelled technique into these MBB studies, which are more and more popular nowadays. The authors′ hospital is one of the first a few organizations to conduct the MBB studies, and has completed almost 20 trials. This review mainly focused on the study design from the investigators′ viewpoints, involving the related rules and regulations, both at home and abroad, and the protocol design, so as to provide our thinkings for references and benefit to the new drug clinical trial in the future.
马晟, 易玲, 缪丽燕. 同位素标记药物物质平衡及生物转化临床研究进展[J]. 中国药学杂志, 2020, 55(14): 1184-1188.
MA Sheng, YI Ling, MIAO Li-yan. Progress in Development of Human Radiolabelled Mass Balance and Biotransformation Studies. Chinese Pharmaceutical Journal, 2020, 55(14): 1184-1188.
NATALIA P, LIN X, CHANDRA P. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? [J]. Chem Res Toxicol, 2012,25(3):513-531.
[2]
ROFFEY S J, OBACH R S, GEDGE J I, et al. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs [J]. Drug Metab Rev, 2007,39(1):17-43.
[3]
MALLER R K, MCIVER F A, HEIDELBERGER C. Studies on OPSPA. Ⅲ. Distribution and excretion of radioactivity following administration of opspa-c-14 and opspa-p-32 to humans [J]. Cancer Res, 1957,17(4):291-295.
[4]
MUKHERJEE K L, HEIDELBERGER C, JAVID M, et al. Studies on fluorinated pyrimidines .17. Tissue distribution of 5-fluorouracil-2-c14 and 5-fluoro-2-deoxyuridine in cancer patients [J]. Cancer Res, 1963,23(1):67.
[5]
FDA. Radioactive drug research committee (rdrc) program[EB/OL]. USA, 1975. [2019-11-29]. https://www. fda. gov/drugs/science-and-research-drugs/radioactive-drug-research-committee-rdrc-program.
EPA. Health effects test guidelines, oppts 870.7485, metabolism and pharmacokinetics[EB/OL].USA,1998.[1998-08]. https://nepis.epa.gov/Exe/ZyPDF.cgi/P100IRXG.PDF?Dockey=P100IRXG.PDF.
[8]
FDA. Guidance for industry: safety testing of drug metabolites[EB/OL]. USA, 2008. [2020-03-05]. https://www.fda.gov/media/72279/download.
[9]
FDA. Guidance for industry and researchers, the radioactive drug research committee: human research without an investigational new drug application[EB/OL]. USA, 2010. [2010-08]. https://www.fda.gov/media/76286/download.
[10]
FDA. CFR 21 361:prescription drugs for human use generally recognized as safe and effective and not misbranded: Drugs used in research[EB/OL]. USA, 2015. [2019-04-01]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1.
[11]
ICH. S9 Nonclinical Evaluation for anticancer pharmaceuticals[EB/OL]. USA, 2010. [2010-03]. http://www.fda.gov/ media/ 73161/download.
[12]
ICH. M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, questions and answers[EB/OL]. USA, 2013. [2013-03]. https://www.fda.gov/media/82725/download.
[13]
EMA. Guideline on the investigation of drug interactions[EB/OL]. USA, 2012. [2013-01-01]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.
[14]
EMA. Guideline on the evaluation of anticancer medicinal products in man[EB/OL]. USA, 2012. [2017-11-20]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-4_en.pdf.
[15]
EASHW. Directive 2013/59/Euratom-Protection against ionising radiation[EB/OL]. EU, 2013. [2019-07-25]. https://osha.europa.eu/en/legislation/directives/directive-2013-59-euratom-protection-against-ionising-radiation.
[16]
ICH. M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals[EB/OL].USA, 2010. [2010-01]. https://www.fda.gov/media/71542/download.
[17]
NIJENHUIS C M, SCHELLENS J H M, BEIJNEN J H. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review [J]. Drug Metab Rev, 2016,48(2):266-280.
[18]
ROFFEL A F, VAN MARLE S P, VAN LIER J J, et al. An evaluation of human adme and mass balance studies using regular or low doses of radiocarbon [J]. J Label Compd Radiopharm, 2016,59(14):619-626.
[19]
SOLON E G. Autoradiography techniques and quantification of drug distribution [J]. Cell Tissue Res, 2015,360(1):87-107.
[20]
ROOSENDAAL J, ROSING H, LUCAS L, et al. Mass balance and metabolite profiling of c-14-guadecitabine in patients with advanced cancer[J]. Invest New Drugs, 2019. DOI: 10.1007/s10637-019-00854-9.
[21]
GUPTA N, ZHANG S, PUSALKAR S, et al. A phase Ⅰ study to assess the mass balance, excretion, and pharmacokinetics of c-14-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors [J]. Invest New Drugs, 2018,36(3):407-415.
[22]
MARK A S. Adding value through accelerator mass spectrometry-enabled first in human studies [J]. J Label Compd Radiopharm, 2016,59(14):640-647.
[23]
MENG J, LIU X Y, MA S, et al. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein [J]. Acta Pharmacol Sin(中国药理学报), 2019,40(7):980-988.
2020, Vol. 55 
